Cure Today3h
Neoadjuvant Tyvyt With Chemo Improve Responses in Resectable, Locally Advanced ESCC
In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an ...
Magnetic pulses boost breast cancer chemo, potentially reducing side effects: NUS study
Researchers from the National University of Singapore (NUS) have found that non-invasive magnetic pulses can enhance the ...
FDA approves Datroway for HR-positive, HER2-negative breast cancer
The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...
UroGen: Upcoming PDUFA, Some Concerns Remain
Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.